OT-A201 / Onward Therap, Biomunex - LARVOL DELTA

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints (PRNewswire) - "Onward Therapeutics SA...announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress. The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoral activity of OT-A201. The study is a European multicenter and open-label study that will be conducted in two parts. The first part is a dose escalation stage of OT-A201 as single agent in patients with selected relapsed/refractory hematological malignancies or advanced/metastatic solid tumors."

Trial status • Hematological Malignancies • Oncology • Solid Tumor

Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer (Businesswire) - "Biomunex Pharmaceuticals (Biomunex)...announced today the enrollment in 2023 of the first patient in a Phase 1 clinical trial conducted by Onward Therapeutics SA (Onward Therapeutics)....This Phase 1 clinical trial is a European multicenter and open-label study that is divided in two parts."

Trial status • Hematological Malignancies • Oncology • Solid Tumor

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Onward Therapeutics | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Monotherapy • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Onward Therapeutics

Combination therapy • Monotherapy • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor